Accessibility Information

Users of assistive technologies such as screen readers should use the following link to activate Accessibility Mode before continuing: Learn more and Activate accessibility mode.

Medication Discovery Using Rat Relapse Models

Solicitation Number: N01DA-14-8917
Agency: Department of Health and Human Services
Office: National Institutes of Health
Location: National Institute on Drug Abuse
  • Print

Note:

There have been modifications to this notice. You are currently viewing the original synopsis. To view the most recent modification/amendment, click here
:
N01DA-14-8917
:
Presolicitation
:
Added: Jan 15, 2014 4:04 pm

The National Institute on Drug Abuse plans to solicit proposals from offerors having in-house capability to develop methodologies and to perform in vivo rodent behavioral pharmacology for other drug dependence disorders, using drug self-administration reinstatement models. The objectives of this contract are to determine the in vivo efficacy of novel compounds in animal models of relapse. This includes the following tests in animals trained to self-administer cocaine: (1) the ability of test compound to block footshock or other stress-induced reinstatement of responding after a period of experimental extinction; (2) the ability of a test compound to block cocaine-priming-induced reinstatement of responding after a period of extinction; and (3) the ability of a test compound to block the effects of a conditioned cue (previously paired with cocaine) to reinstate responding for cocaine after a period of extinction.


Due to the nature of the compounds which will be evaluated under this contract, it is mandatory that offerors possess a Drug Enforcement Agency (DEA) Research Registration for Schedules II to V in order to handle substances under the Controlled Substances Act of 1970. In addition, the successful offeror must either possess, or demonstrate the ability to obtain a DEA registration for Schedule I controlled substances.


We anticipate the award of one cost reimbursement, severable, level-of-effort contract with a base period of one year with four option years. In addition to the options to extend the contract period of performance, option quantities are also anticipated.


RFP No. N01DA-14-8917 will be available electronically on or about February 4, 2014. You can access the RFP through the FedBizOpps (URL: http://fedbizopps.gov) or through the NIDA website: (URL: http://www.drugabuse.gov/funding/funding-opportunities/nida-requests-contract-proposals-rfps). All information required for the submission of a proposal will be contained in or accessible through the RFP package. Responses to the RFP will be due 45 days from the release date. NIDA will consider proposals submitted by any responsible offeror. This advertisement does not commit the Government to award a contract.


Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons may identify to the Contracting Officer their interest and capability to satisfy the Government's requirement with a commercial item within 15 days of this notice.


Contracting Office Address


NIDA R&D Contracts Management Branch
6001 Executive Boulevard
Room 4211, MSC 9559
Bethesda, Maryland 20892-9559*


*Use Rockville, MD 20852 for Fed-Ex/USPS/Courier/Hand-Delivery

:
6001 Executive Boulevard
Room 4211 - MSC 9559
Bethesda, Maryland 20892
United States
:
Jeffrey R Schmidt,
Contract Specialist
Phone: (301) 443-6677
Fax: (301) 443-7595
:
Brian H O'Laughlin,
Contracting Officer
Phone: (301) 443-6677
Fax: (301) 443-7595